Omega Depot

References

Omega Depot, the first clinical-trial depot in Türkiye, has completed more than 100 projects since 2003 across IMP storage, distribution and study close-out.

IMPinvestigational product
IVDkits and reagents
MDmedical devices
End-to-endoperating model

Operational experience

See our approach in real study scenarios

01

Clinical-trial focus

Medicines, devices, kits and ancillary supplies are assessed against the protocol and intended use. Product type, site plan and target date determine the operating scope.

02

One operational contact

Dependencies between import, customs, storage and distribution become visible in one project flow. The approval owner for each step is clarified at the outset.

03

Quality assurance

Control points, training and document requirements are defined for the agreed service. Deviations and changes are recorded and escalated to the relevant decision owner.

04

Nationwide reach

Shipments from Ankara to research sites are planned around product profile and delivery window. Dispatch and delivery evidence is retained in the project file.

Client-anonymized operating experience

The operating scope of past projects

Client names remain private; vaccine studies are shown by name with their own project figures.

15–25 °C · Multi-site programme

Nationwide supply for a smoking-cessation programme

Project scope224 centres · 164,733 participants · 247,435 medicine boxes

The project summary records medicine supply at 15–25 °C across a network involving 400 physicians and 650 assistant healthcare personnel. The box and participant figures belong to this past programme.

For sponsors: Site-level demand, stock units and the delivery calendar should be defined together at the start of scoping.

Distribution service

15–25 °C · Early access

Physician deliveries in an early-access programme

Project scope73 physicians · 900 medicines · 15–25 °C

A separate early-access summary reports that medicines held at ambient temperature were delivered to 73 physicians. Unlike multi-site study distribution, this example centres on a physician-level recipient plan.

For sponsors: Confirm the physician list, product quantity and authorised recipient before finalising dispatch.

Distribution service

2–8 °C · Phase 3

Coronovac Phase 3

Project scope24 sites · 26,180 vaccines · 2–8 °C

The Coronovac Phase 3 summary records a 24-site scope for vaccines with a 2–8 °C temperature profile. This quantity belongs to this Phase 3 study alone and is not combined with the other vaccine projects.

For sponsors: Site allocation and cold-chain requirements should be specified for each study and shipment plan.

Storage service

2–8 °C · Phase 3

Turkovac Phase 3

Project scope8 sites · 1,290 people × 2 administrations · 2,580 vaccines

The Turkovac Phase 3 summary lists 2,580 vaccines for two administrations to 1,290 people across eight sites under a 2–8 °C profile. Participant, administration and product counts are distinct planning inputs.

For sponsors: Calculate product demand from the administration schedule, not the site count alone.

Storage service

2–8 °C · Phase 2b

Rapel Phase 2b

Project scope41 sites · 4,340 vaccines · 2–8 °C

The Rapel Phase 2b summary records 4,340 vaccines across a 41-site study scope under a 2–8 °C profile. The breadth of the site network is a planning variable separate from product quantity.

For sponsors: Prepare site-level demand, delivery windows and recipient contacts separately.

Storage service

15–25 °C · Non-drug study

Research material for a non-drug clinical study

Project scope14 sites · 4,484 boxes · 15–25 °C

The summary of a clinical study described as non-drug records 4,484 boxes of research material for 14 sites under a 15–25 °C profile. The product is not labelled as a medicine or medical device without a separate classification check.

For sponsors: State the product classification, box/stock unit and site allocation in the initial brief.

Distribution service

International routes · Urgent coordination

Urgent international product shipments

Project scope6 routes · 28–35 hours from origin to destination

Past shipment summaries originating in New Delhi, London, Beijing, New York, Hong Kong and Shanghai cover cell-therapy material, research medicines, kits and consumables. The recorded times run from origin to destination; they are not customs-clearance durations.

For sponsors: For an urgent request, share product class, permit status, origin and target delivery time on one timeline.

Customs coordination

Site activation · Equipment and calibration

Equipment support for clinical sites

Project scope7 sites · more than 50 calibration services

The project summary lists ultra-low freezers, incubators, vaccine refrigerators and centrifuges sourced for seven sites. The same document separately reports more than 50 calibration services; device and calibration counts are not combined as one delivery total.

For sponsors: Define technical needs, installation conditions and calibration ownership for each site at the outset.

Equipment and supply sourcing

Source: past project summaries supplied by Omega. Quantities and times describe only the relevant historical examples, not current capacity or a delivery commitment. The source does not distinguish vaccine doses from vials.

Operating model

From uncertainty to a traceable outcome

Every project follows the same control logic, adapted to product and protocol requirements.

  1. 01

    Define scope

    Product, intended use, quantity and target date are confirmed.

  2. 02

    Validate the route

    Regulatory, documentary, temperature and transport requirements are mapped.

  3. 03

    Execute with control

    The operation follows an approved plan, owners and monitoring points.

  4. 04

    Close the records

    Delivery, deviation and accountability records are archived.

Omega Depot

Plan your next shipment with confidence

Share the product, route and timeline; our team will map a workable operational flow.

Talk to our team